https://www.selleckchem.com/products/cx-5461.html Absolute risk for infection was significantly lower in 5ARI users compared to nonusers, 42.3% (399/944) vs. 47.2% (446/944), respectively (absolute risk reduction (ARR) 4.9%, OR 0.81, 95% CI 0.67-0.97, p=0.026). Unconditional multivariable logistic regression analysis of the entire study cohort of 55,100 men confirmed the protective association of 5ARI use (ARR 5.3%, OR=0.877, 95% CI 0.774-0.995, p=0.042). Use of 5ARIs was not associated with disease severity. Use of 5ARIs in men without prostate cancer was associated with a reduction in community acquired SARS-CoV-2 infection. Use of 5ARIs in men without prostate cancer was associated with a reduction in community acquired SARS-CoV-2 infection.[Figure see text]. Statin treatment reduces the risk of atherosclerotic cardiovascular disease but is associated with a modest increased risk of type 2 diabetes, especially in those with insulin resistance or prediabetes. Our objective was to determine the physiological mechanism for the increased type 2 diabetes risk. Approach and Results We conducted an open-label clinical trial of atorvastatin 40 mg daily in adults without known atherosclerotic cardiovascular disease or type 2 diabetes at baseline. The co-primary outcomes were changes at 10 weeks versus baseline in insulin resistance as assessed by steady-state plasma glucose during the insulin suppression test and insulin secretion as assessed by insulin secretion rate area under the curve (ISR ) during the graded-glucose infusion test. Secondary outcomes included glucose and insulin, both fasting and during oral glucose tolerance test. Of 75 participants who enrolled, 71 completed the study (median age 61 years, 37% women, 65% non-Hispanic White, median body mass index, 27.8 kg/m ). Atorvastatin reduced LDL (low-density lipoprotein)-cholesterol (median decrease 53%, <0.001) but did not change body weight. Compared with baseline, atorvastatin increased insulin resistance (